loading page

The effects of L-Carnitine supplementation on inflammatory markers, clinical status, and 28 days, mortality in critically ill patients: A double-blind, randomized, placebo-controlled trial
  • +8
  • Farveh Yahyapoor,
  • Alireza Sedaghat,
  • AWAT FEIZI,
  • Mohammad Bagherniya,
  • Naseh Pahlavani,
  • majid khadem rezaian,
  • Mohammad Safarian,
  • Sheikh Mohammed Shariful Islam,
  • Mostafa Arabi,
  • Sudiyeh hejri zarifi,
  • Abdolreza Norouzy
Farveh Yahyapoor
Mashhad University of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Alireza Sedaghat
Mashhad University of Medical Sciences
Author Profile
AWAT FEIZI
Isfahan University of Medical Sciences
Author Profile
Mohammad Bagherniya
Isfahan University of Medical Sciences
Author Profile
Naseh Pahlavani
Mashhad University of Medical Sciences
Author Profile
majid khadem rezaian
Mashhad University of Medical Sciences
Author Profile
Mohammad Safarian
Mashhad University of Medical Sciences
Author Profile
Sheikh Mohammed Shariful Islam
Deakin University
Author Profile
Mostafa Arabi
Mashhad University of Medical Sciences
Author Profile
Sudiyeh hejri zarifi
Mashhad University of Medical Sciences
Author Profile
Abdolreza Norouzy
Mashhad University of Medical Sciences
Author Profile

Abstract

Aim: Critical ill patients experience catabolic stress which results in the systemic inflammatory response. The inflammatory response is associated with increased complications including infection, multi-organ dysfunction, increased length of ICU stays, and mortality. L-Carnitine supplementation may play an important role in these patients by regulating inflammatory cell function. The purpose of the present study was to investigate the effect of L-Carnitine supplementation on clinical status, inflammatory markers, and mortality rate in critically ill patients admitted in the intensive care unit(ICU) Methods: This randomized, double-blind, placebo-controlled trial was performed on critically ill patients. Subjects were randomly assigned into placebo (n=27) and L-Carnitine (n=27) groups. L-Carnitine (3000mg/day) was administered via nasogastric tube for the intervention group for 7 days while the other group received a placebo for the same duration. Serum levels of inflammatory markers including C-reactive protein (CRP) and interleukin-6 (IL-6) were measured. Nutritional status and the acute physiology and chronic health evaluation (APACHE) score, sequential organ failure assessment (SOFA) score, and 28-day mortality were also recorded. Results: Fifty-one critically ill patients completed the study. L-Carnitine supplementation significantly reduced the levels of CRP (mean change± SE: -34.9 ± 6.5) and IL-6 (mean change ±SE: -10.64 ± 2.16) compared to the baseline, which are both statistically significant compared with the control group (p<0.05). The SOFA and APACHE scores were significantly reduced in the L-Carnitine group compared with the placebo group (p=0.02 and p<0.001, respectively). Conclusions: L-Carnitine supplementation has substantial beneficial effects on inflammatory and clinical outcomes of critically ill patients.